Press releases

26 March, 2024

Regulatory

Resolutions at the Extraordinary General Meeting in Abliva AB (publ)

Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva” or the ”Company”) has today 26 March 2024 held an Extraordinary General Meeting. A summary of the resolutions follows. The resolutions were passed unanimou ...

23 February, 2024

Regulatory

Abliva AB Year-End Report January – December 2023

40 Patients Enrolled in Wave 1 of the FALCON Study | Fast Track Designation for KL1333 | Orphan Drug Designation for NV354 in both US and Europe

22 February, 2024

Regulatory

Notice of Extraordinary General Meeting of Abliva AB (publ)

The shareholders of Abliva AB (publ), corporate identity number 556595-6538, (the “Company”), are hereby convened to the Extraordinary General Meeting (the “EGM”) to be held at 3 p.m. on Tuesday 26 Ma ...

17 November, 202319 February, 2024

Regulatory

Abliva AB Interim Report January – September 2023

KL1333 Received FDA Fast Track Designation | The FALCON Study Reached an Important Milestone

23 May, 2023

Regulatory

Abliva AB Interim Report January – March 2023

Patient screening ongoing in the FALCON study | Orphan Drug Designation for NV354

5 May, 2023

Regulatory

Resolutions from Annual General Meeting in Abliva AB (publ) on May 5, 2023

Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva” or the ”Company”) today on May 5, 2023, held its Annual General Meeting (“AGM”). A summary of the resolution follows.

4 May, 2023

Regulatory

Amendment of the Nomination Committee’s proposal for Abliva’s Annual General Meeting in 2023

The notice for Abliva’s Annual General Meeting (AGM) 2023 was announced in a press release on April 4th, 2023. The Nominating Committee’s proposal for the election of Board members was [&h ...

4 April, 2023

Regulatory

Notice of Annual General Meeting of Abliva AB (publ)

The shareholders of Abliva AB (publ), corporate identity number 556595-6538, are hereby convened to the Annual General Meeting, held at 10 a.m. on Friday, 5 May 2023 at Medicon Village, Scheeletorget ...

8 March, 2023

Regulatory

Resolutions at the Extraordinary General Meeting in Abliva AB (publ)

Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva” or the ”Company”) has today held an Extraordinary General Meeting. A summary of the resolutions follows.

24 February, 2023

Regulatory

Abliva AB Year-End Report January – December 2022

A successful financing enabled the start of the FALCON study with KL1333

13 February, 2023

Regulatory

Notice of Extraordinary General Meeting of Abliva AB (publ)

The shareholders of Abliva AB (publ), corporate identity number 556595-6538, are hereby convened to the Extraordinary General Meeting (the “EGM”) to be held at 11.00 a.m. on Wednesday 8 March 2023 at ...

13 February, 2023

Regulatory

Abliva Nomination Committee to propose Edwin Moses as a new Board member and incoming Chair of the Board of Directors at upcoming General Meetings

The Nomination Committee of Abliva AB proposes that Dr. Edwin Moses be elected as a new Board member of the Company through a shareholder vote at the EGM on March 8, 2023. Dr. Moses, who has over 30 y ...